e-learning
resources
Milan 2017
Tuesday, 12.09.2017
Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Overall survival analysis and characterization of an EGFR mutated non small cell lung cancer (NSCLC) population
F. Aguiar (Paredes, Portugal)
Source:
International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up
Session:
Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up
Session type:
Thematic Poster
Number:
4261
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Aguiar (Paredes, Portugal). Overall survival analysis and characterization of an EGFR mutated non small cell lung cancer (NSCLC) population. 4261
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011
Cyclooxygenase(COX)-2 is over-expressed in non small cell lung cancer (NSCLC) and is a potential target for treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 400s
Year: 2002
Characteristics and prognostic relevance of
p
53 gene mutations in Polish non small cell lung cancer (NSCLC) patients
Source: Eur Respir J 2005; 26: Suppl. 49, 92s
Year: 2005
One year survival differences of EGFR- and KRAS-mutated advanced non-small cell lung cancer (NSCLC) compared to the wildtype population
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
Quantitative RT-PCR 3-gene expression signature predicts survival in early-stage non-small cell lung cancer (NSCLC) patients (pts)
Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases
Year: 2008
Epithelial growth factor receptor (EGFR) mutation status and the treatment of non-small cell lung cancer (NSCLC): A population based quality assurance analysis
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015
Investigation of a relationship between NF-KB1A gene polymorphism and non small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008
Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
Source: Eur Respir J 2011; 37: 624-631
Year: 2011
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival
Source: Eur Respir J 2007; 30: Suppl. 51, 280s
Year: 2007
Staging with FDG-PET/CT influences stage-specific survival in non small cell lung cancer (NSCLC)
Source: Annual Congress 2011 - Imaging in oncology and infectious diseases
Year: 2011
Validation and comparison of several published prognostic systems for patients with small cell lung cancer
Source: Eur Respir J 2011; 38: 657-663
Year: 2011
Analysis of the prognosis value of the mitochondrial activity in resected non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Analysis of survival and characteristics of patients with non-small cell lung carcinoma (NSCLC) stage IV depending on molecular markers
Source: International Congress 2019 – Biology and prognosis of lung cancer
Year: 2019
The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC)
Source: Eur Respir J 2004; 24: Suppl. 48, 672s
Year: 2004
Survival prognosis and target therapy best response in adenocarcinoma lung cancer pts with mutation EGFR gene
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009
C-kit (CD 117): a new prognostic factor in small cell lung cancer (SCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 478s
Year: 2001
The analysis of CHEK2 gene mutation in small cell lung cancer
Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases
Year: 2021
Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC)
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept